The present invention relates to anti-HCV dihaloacetamide compounds in
synergistic combination with an interferon and/or ribavirin and
pharmaceutical compositions thereof for inhibition of the replication of
HCV virus. The present invention also relates to the use of the
compositions to inhibit HCV replication and/or proliferation and to treat
or prevent HCV infections.